Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciforadenant + Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT04280328Phase 1Completed
- Sponsor
- Corvus Pharmaceuticals
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ciforadenant in multiple myeloma (MM), sponsored by Corvus Pharmaceuticals. Primary endpoints: Safety and tolerability of ciforadenant in combination with daratumumab up to 24 months and Safety and tolerability (DLT timeframe) at 28 days. Started Feb 2020; status: completed.
02
Drugs
ciforadenant
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04280328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04280328.